The Four R s. Repair Reoxygenation Repopulation Redistribution. The Radiobiology of Small Fraction Numbers. The Radiobiology of Small Fraction Numbers

Similar documents
Radiobiology of fractionated treatments: the classical approach and the 4 Rs. Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica

HALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy

The Radiation Biology of Dose Fractionation: Determinants of Effect

Fractionation: why did we ever fractionate? The Multiple Fractions School won! Survival curves: normal vs cancer cells

New Thinking on Fractionation in Radiotherapy

Cell survival following high dose rate flattening filter free (FFF) and conventional dose rate irradiation

Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation.

Clinical Applications of Brachytherapy Radiobiology. Radiobiology is Essential

BASIC CLINICAL RADIOBIOLOGY

Radiation Oncology. Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology

The Radiobiological Four "R"s of Hypofractionation. Brian Marples PhD Beaumont Health Systems

Hypofractionated radiation therapy for glioblastoma

Radiobiological principles of brachytherapy

Radiotherapy physics & Equipments

UNC-Duke Biology Course for Residents Fall

7/16/2009. An overview of classical radiobiology. Radiobiology and the cell kill paradigm. 1. Repair: Radiation cell killing. Radiation cell killing

ISOEFFECT CALCULATION IN HDR BRACHYTHERAPY (BASIC CLINICAL RADIOBIOLOGY)

Radiation Biology in Brachytherapy

Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer

I TESSUTI: Dott.ssa Liliana Belgioia Università degli Studi di Genova

Radiobiologia: High dose per fraction. Lidia Strigari Laboratorio di Fisica Medica e Sistemi Esperti SBRT

Therapeutic ratio - An Overview. Past Present Future Prof Ramesh S Bilimaga

The Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation. Roberto Alonzi Mount Vernon Cancer Centre

An introduction to different types of radiotherapy

Hypofractionation in prostate cancer radiotherapy

An Update on Radiation Therapy for Prostate Cancer

RADIOBIOLOGICAL PRINCIPLES IN INTRAVASCULAR IRRADIATION

PRINCIPLES OF RADIATION ONCOLOGY

FRACTIONATION AND PROTRACTION FOR RADIOTHERAPY OF PROSTATE CARCINOMA

Non-classical radiobiology relevant to high-doses per fraction

Hidden Issues in the Use of LQ. Disclosure

The dependence of optimal fractionation schemes on the spatial dose distribution

Hypofractionation in particle therapy. Marco Durante

Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations*

ROLE OF ALTERED FRACTIONATION & CHEMORADIATION IN HEAD AND NECK CANCER

WHAT HYPOFRACTIONATED PROTOCOLS SHOULD BE TESTED FOR PROSTATE CANCER?

Phase II study of FFF-SBRT in 5 fractions for low and intermediate risk prostate cancer

HDR vs. LDR Is One Better Than The Other?

IMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia

Clinical experience with TomoDirect System Tangential Mode

Radiobiological Models in Brachytherapy Planning and Evaluation

Whole Breast Irradiation: Class vs. Hypofractionation

Individualized dosimetry treatment planning for liver irradiation

CYBERKNIFE SBRT FOR THE TREATMENT OF PROSTATE CANCER: 5 VS. 44 FRACTIONS THE PHILADELPHIA CYBERKNIFE CENTER EXPERIENCE

The temporal pattern of dose delivery in external beam radiotherapy

The Impact of Cobalt-60 Source Age on Biologically Effective Dose in Gamma Knife Thalamotomy

Innovazioni tecnologiche in Radioterapia" Sergio Fersino Radioterapia Oncologica

Understanding Radiation Therapy. For Patients and the Public

TFY4315 STRÅLINGSBIOFYSIKK

Radiotherapy Advances

Palliative radiotherapy in lung cancer

Radiobiological modelling applied to Unsealed Source (radio) Therapy

In Honor of Jack Fowler

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

Neutron Radiotherapy: Past, Present, and Future Directions

Research Article A Mathematical Model of Tumor Volume Changes during Radiotherapy

Spinal Cord Doses in Palliative Lung Radiotherapy Schedules

External Beam Radiotherapy for Prostate Cancer

Disclosure. Paul Medin teaches radiosurgery courses sponsored by BrainLAB Many animals (and humans) were harmed to make this presentation possible!

Risk of secondary cancer induced by radiotherapy

RADIOBIOLOIGCALLY BASED TREATMENT PLANNING: THE NEXT FRONTIER. Teddy LaMaster, MS

CyberKnife Monotherapy for Prostate Cancer

Post-Lumpectomy Radiation Techniques and Toxicities

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)

The Role of Radiotherapy in Metastatic Breast Cancer. Shilpen Patel MD, FACRO Associate Professor Departments of Radiation Oncology and Global Health

Changing Paradigms in Radiotherapy

SBRT in early stage NSCLC

Overview of Clinical and Research Activities at Georgetown University Hospital

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer

Principle of Radiation Therapy

Cell Survival vs Irradiation dose

4.1.1 Dose distributions LKB effective volume or mean liver dose? The critical volume model TUMOUR CONTROL...

A SIMPLE METHOD OF OBTAINING EQUIVALENT DOSES FOR USE IN HDR BRACHYTHERAPY

Complications/Adverse Effects of Radiotherapy

Lecturer: Dr. David Murray March 18th, 2008

Can the two mechanisms of tumor cell killing by radiation be exploited for therapeutic gain?

22.55 Principles of Radiation Interactions Name: Spring 2004 Professor Coderre Exam 2 April 30, 2004

HDR Brachytherapy: Results and Future Studies in Monotherapy

Radiation Oncology 101: A Whole Field, 120 Years, and 100 s of Diseases in Under 30 min

Introduction to clinical Radiotherapy

Radiation Damage Comparison between Intensity Modulated Radiotherapy (IMRT) and Field-in-field (FIF) Technique In Breast Cancer Treatments

Review of brachytherapy in

HDR Applicators and Dosimetry*

Page 1. Helical (Spiral) Tomotherapy. UW Helical Tomotherapy Unit. Helical (Spiral) Tomotherapy. MVCT of an Anesthetized Dog with a Sinus Tumor

Collection of Recorded Radiotherapy Seminars

Feasibility of 4D IMRT Delivery for Hypofractionated High Dose Partial Prostate Treatments

Determination and Use of Radiobiological Response Parameters in Radiation Therapy Optimization. Panayiotis Mavroidis

Combined drug and ionizing radiation: biological basis. Prof. Vincent GREGOIRE Université Catholique de Louvain, Cliniques Universitaires St-Luc

New Radiation Treatment Modalities in the Treatment of Lung Cancer

Tecniche Radioterapiche U. Ricardi

Flattening Filter Free beam

CyberKnife Radiotherapy For Localized Prostate Cancer: Rationale And Technical Feasibility

How can we Personalize RT as part of Breast-Conserving Therapy?

It s All About Margins. Maaike Milder, Ph.D. Accuray Symposium April 21 st 2018

Modelling the induction of cell death and chromosome damage by therapeutic protons

Beyond The Dvh - Spatial And Biological Radiotherapy Treatment Planning

Isotopes and Palliative Radiotherapy for bone metastases

by Lingshu Yin B.Sc. Nanjing University 2006 A THESIS SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENT FOR THE DEGREE OF Master of Science

SBRT TREATMENT PLANNING: TIPS + TRICKS. Rachel A. Hackett CMD, RT(T)

Stereotactic Radiosurgery. Extracranial Stereotactic Radiosurgery. Linear accelerators. Basic technique. Indications of SRS

Transcription:

The Radiobiology of Small Fraction Numbers David J. Brenner, PhD, DSc Center for Radiological Research Columbia University Medical Center djb3@columbia.edu The Radiobiology of Small Fraction Numbers 1. Single-Fraction Radiotherapy What determines optimal fractionation for conventional radiotherapy? The Four R s Repair Reoxygenation Repopulation Redistribution 1

DNA repair results in reduced cell killing when a treatment is fractionated Multiple fractions Single fraction Dose Different types of tissue respond quantitatively differently to changes in fractionation Single fraction TUMOR Less curvy Less sensitive to changes in protraction Quantified by large α/β ratio ( 10 Gy) Single fraction Dose Multifraction Multifraction LATE-RESPONDING NORMAL TISSUE More curvy More sensitive to changes in protraction Quantified by small α/β ratio ( 5 Gy) So why do we fractionate? Late-responding normal tissues are more sensitive to changes in fractionation (small α/β) than are early-responding tissues such as tumors (large α/β) So fractionation spares late-responding tissues compared to most tumors 2

A basis for these α/β differences In vitro: non-cycling cells are associated with low α/β cycling cells are associated with high α/β Tumor: Cycling cells: High α/β Late Late-responding responding normal Normal tissue: tissue: Non-cycling Few cycling cells: cells: Low Low α/β α/β Hypoxia / Reoxygenation: The other reason we fractionate Fractionation results in reoxygenation Reoxygenation in ~24 hrs Reoxygenation in ~24 hrs Reoxygenation in ~24 hrs, etc. 3

Hypoxia and malignancies Almost all malignant tumors, even a few mm in diameter, contain hypoxic cells A malignant tumor containing even a small hypoxic fraction would require an exceedingly high single-fraction dose for sterilization Therefore fractionation appears highly advantageous when attempting to cure malignant tumors Accelerated Repopulation As a tumor shrinks, surviving clonogens proliferate at an accelerated rate So for external beam RT of tumors Must fractionate treatment to overcome hypoxia for differential response with late effects Must prolong treatment to limit early sequellae Would like to shorten treatment to prevent accelerated repopulation 4

For stereotactic RT of malignant tumors.. Must fractionate treatment to overcome hypoxia for differential response with late effects Must prolong treatment to limit early sequellae Would like to shorten treatment to prevent accelerated repopulation Is the biology different at high doses per fraction? Very high doses per fraction of radiation might trigger an entirely different method of cell kill via an anti-angiogenic pathway involving endothelial apoptosis Is the standard model (tumor control related primarily to radiation killing of tumor clonogens) inapplicable at high doses? Predicted TCD 50 based on in-vitro cell survival, vs observed TCD 50 Observed Predicted The single-fraction dose to inactivate experimental tumors is well predicted by measured clonogenic fraction and in-vitro radiation-induced cell survival Tumors 5

Other papers showing correlations between in vitro tumor-cell radiosensitivty and in vivo tumor control at high single doses / fraction Ablative Radiotherapy: A different dominant mechanism for tumor control at high doses per fraction? The LQ model fails to predict high dose / Fx tumor control so some new biology must be going on The LQ model will certainly fail at very high single doses But this doesn t imply that the standard model (tumor control related primarily to radiation killing of tumor clonogens) is wrong Nor does it contradict the rationale that fractionation will improve outcome after RT for tumors Fractionation for malignant tumors All malignant tumors, small or large, slow or fast growing, sensitive or resistant, will be more effectively treated with fractionation than with a single fraction 6

Stereotactic radiosurgery / ablative RT The Bottom Line Stereotactic radiosurgery and SABR have had impressive success in treating some malignancies, particular in the brain and lung But, for any given malignancy, better results should be obtained with fractionation There is no need for conventional fractionation, 5-10 fractions is optimal For vascular disease and benign tumors, fractionation may only be needed if the lesions are large The Radiobiology of Small Fraction Numbers 2. Hypofractionated radiotherapy In most RT scenarios, we fractionate to take advantage of the differential α/β ratio between tumor and late responding normal tissue non-cycling cells are associated with low α/β cycling cells are associated with high α/β Tumor: Cycling cells: High α/β Late-responding normal Normal tissue: tissue: Non-cycling Few cycling cells: cells: Low Low α/β α/β 7

Prostate Cancer Prostate tumors are not typical of most tumors, containing far fewer cycling cells Do prostate tumors have the typical differential response to fractionation for tumor control relative to late-responding tissues? What is an appropriate α/β value for prostate tumors? Based on clinical data from implant and external beam data... α/β for prostate cancer = 1.5 Gy [95% CI: 0.8-2.2] comparable with typical α/β for late-responding normal tissues Brenner and Hall 1999 If the α/β ratio for prostate cancer is comparable to that for normal tissue. We lose one of the fundamental rationales for using many fractions or using low dose rate So hypo-fractionation or HDR rather than conventional fractionation or LDR become potential options for prostate RT 8

Since the 1999 estimate of α/β, there have been more than 70 further papers in the literature relating to α/β values for prostate Two recent large studies of α/β for prostate 5,969 patients α/β= 1.4 Gy (95% CI 0.9-2.2) 5,093 patients α/β= 1.55 Gy (95% CI 0.46-4.52) If α/β for prostate cancer is about the same as for surrounding late-responding normal tissue... Less rationale for using many fractions or LDR Fewer fractions at the right dose would give 1. The same tumor control and late sequelae as current regimens 2. Patient convenience 3. Financial / resource advantages 9

Tumor control / toxicity from randomized studies: Hypofractionation vs conventional fractionation Our findings suggest that late toxicity is equivalent between the two treatment groups, and that the hypofractionated schedule used in this trial is superior to the conventional fractionation in terms of FFBF Tumor control / toxicity from randomized studies: Hypofractionation vs conventional fractionation A therapeutic advantage of the hypofractionated compared to the conventional dose schedule for RT of prostate cancer was evident at 90 months in the present study Is this mechanistically-based argument for hypofractionation unique to prostate? Prostate tumors are not typical of most tumors, containing far fewer cycling cells This does not apply to most other tumor types Perhaps it applies to melanoma? 10

Melanoma is a slow-growing tumor with few dividing cells α/β= 0.57 (95% CI: 1.07 2.5) Successful hypofractionation for choroidal melanoma Is this mechanistically-based argument for hypofractionation unique to prostate? Prostate tumors are not typical of most tumors, containing far fewer cycling cells This does not apply to most other tumor types Perhaps it applies to melanoma? Perhaps it applies to some other early-stage tumors? 11

What about early-stage breast cancer? Much interest in accelerated partial breast irradiation for early-stage breast cancer NSABP B-39/RTOG 0413: 3.4 or 3.85 x 10 fractions BID 2,236 patients α/β= 4.6 Gy (95% CI 1.1-8.1) What about lung? α/β= 8.2 Gy (95% CI 7.0-9.4) How much you need to worry about the effects of hypofractionation on normal tissue will depend very much on whether the normal tissue is a serial or a parallel organ SERIAL Dose PARALLEL NTCP Dose e.g., brain, bladder, rectum, spinal cord e.g., lung, kidney Goitein 2008 12

When the goal is to optimize the therapeutic ratio between tumor control and late complications, basic radiobiological principles tell us that we should fractionate Prostate is a mechanistically understood exception Melanoma and possibly early breast cancer may likewise be exceptions No such radiobiological rationale appears to exists for lung hypofractionation, but the parallel nature of normal lung tissue may well permit less fractionation than at other sites, when the irradiated volume is small This speaker does not think there is persuasive evidence for new radiobiology at high doses per fraction radiobiology X radiobiology X Meet the new boss same as the old boss! 13